Azd4045

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

12 competitors in Relapsed or Refractory Multiple Myeloma

#DrugCompanyPhaseTrials

1

Velcade

SShilpa Grover, MD, MPH

Phase 3

12

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

13

Decadron

AAspen Global Incorporated

Phase 3

14

Mezigdomide

Bristol-Myers Squibb

Phase 3

15

Actemra

Roche

Phase 1

16

Elranatamab

Pfizer

Phase 1

17

Darzalex

Johnson & Johnson

Preclinical

18

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

19

Cevostamab

Roche

Phase 1

110

JNJ-79635322

Johnson & Johnson

Phase 1

1Show 3 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Relapsed or Refractory Multiple Myeloma1 trial

A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Efficacy of AZD4045, an Allogeneic Chimeric Antigen Receptor-T Cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

Not yet recruiting·AstraZeneca·Preclinical·NCT07681596·101 enrolled

Details

Drug Info

Related News